FindTrial
Sign In

Clinical representation and outcomes of the Tumor Lysis Syndrome in critically ill patients

EpideMiologY, clinical preSentation and ouTcomEs of patients with tumoR lYsis syndrome in critically ill [MYSTERY study] - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/04/084439
Enrollment
200
Registered
2025-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Nil: NA Control Intervention1: Nil: NA

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients admitted to the ICU with diagnosis of tumor lysis syndrome as the Cairo Bishop definition(clinical or laboratory criteria)

Exclusion criteria

Exclusion criteria: 1. Etiology of metabolic derangement proved to be unrelated to TLS 2. Pregnant patients 3. Incomplete Data set

Design outcomes

Primary

MeasureTime frame
ICU mortality at 28 daysTimepoint: 28 days—

Secondary

MeasureTime frame
1.Hospital Mortality 2.Need for renal replacement therapy 3.Length of ICU stay (ICU-LOS), length of hospital stay (Hospital LOS) 4.Sensitivity and specificity of each Cairo Bishop criteria for predicting TLS 5.Identify risk factors for TLS 6.Identify factors associated with poor outcomes in TLS patients Timepoint: 28 days—

Countries

India

Contacts

Public ContactDr Atul Kulkarni

Tata Memorial Hospital

kaivalyaak@yahoo.co.in9869077526

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026